Johnson & Johnson
Analysis Terminal
AI Sector Synthesis
Johnson & Johnson recently announced new data from its Phase 3 MajesTEC-3 study, demonstrating sustained disease control and survival benefits with TECVAYLI plus DARZALEX FASPRO for patients with relapsed or refractory multiple myeloma. The company is also noted as an elite dividend stock with a diversified pipeline, recognized for its consistent dividend increases, indicating financial stability.
Latest Market News
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
Surgical Devices Market Size to Worth USD 27.14 Billion by 2030, at a CAGR of 14.7% – MarketsandMarkets™
Delray Beach, FL, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global surgical devices market will grow from USD 188.74 billion in 2026 to USD 296.76 billion by 2031, at a CAGR of 9.5% during the forecast period. Market growth is driven by the increasing aging population, rising surgical procedures, adoption of minimally invasive and robotic surgeries, technological advancements, and expanding healthcare infrastructure globally. Get PDF Brochure - Market Data & Segmentation
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1-3 prior lines of therapy.1,2
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.
Johnson & Johnson: What the Street’s Reaction to OTTAVA Actually Reveals About the Stock
Key TakeawaysJohnson & Johnson’s MedTech segment, the business OTTAVA sits inside, grew from $7. 89 billion to $8.
Crystalys Therapeutics Strengthens Board of Directors and Leadership Team as Dotinurad Advances Through Global Phase 3 Development
Crystalys Therapeutics Inc. ('Crystalys' or 'the Company'), a clinical-stage biopharmaceutical company focused on addressing the significant unmet medical needs of patients living with gout, today announced a series of leadership appointments that further strengthen the Company as it advances dotinurad through its registrational program.
Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now
Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil
2 Stocks to Buy Hand Over Fist if a Stock Market Crash Is Coming
You can take these companies' dividends straight to the bank.
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie
Johnson & Johnson vs. AbbVie valuation: JNJâs P/E & PEGY premium looks justified by a strong balance sheet, buybacks, and more. Read the full analysis here.
Johnson & Johnson is a leading entity in the Pharmaceuticals sector, headquartered in US.
Professional Notice
Information is for educational purposes only. Market data is sourced via global nodes and is not financial advice.